Solventum (NYSE:SOLV) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen downgraded shares of Solventum (NYSE:SOLV) from a buy rating to a hold rating in a research report sent to investors on Saturday.

Other equities analysts also recently issued research reports about the company. Weiss Ratings upgraded Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday. Wells Fargo & Company lowered their price target on Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 6th. Wedbush upped their price target on Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. BTIG Research increased their price objective on Solventum from $91.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Stifel Nicolaus lifted their price objective on Solventum from $90.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Solventum has an average rating of “Moderate Buy” and an average target price of $91.64.

Solventum Stock Performance

NYSE:SOLV opened at $89.64 on Friday. Solventum has a 12-month low of $62.38 and a 12-month high of $90.00. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $15.26 billion, a PE ratio of 10.96, a price-to-earnings-growth ratio of 1.15 and a beta of 0.60. The firm has a 50-day moving average price of $80.91 and a 200 day moving average price of $75.05.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. The firm had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.69 earnings per share. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Research analysts anticipate that Solventum will post 7.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of SOLV. CrossGen Wealth LLC acquired a new position in shares of Solventum in the 4th quarter worth approximately $25,000. Measured Wealth Private Client Group LLC acquired a new stake in Solventum during the 3rd quarter valued at $25,000. CYBER HORNET ETFs LLC acquired a new stake in Solventum during the 2nd quarter valued at $28,000. Modus Advisors LLC acquired a new stake in Solventum during the 4th quarter valued at $30,000. Finally, Clearstead Trust LLC raised its position in Solventum by 61.0% in the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after purchasing an additional 150 shares during the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.